Association of ABCB1 polymorphisms with lipid homeostasis and liver injury response to atorvastatin in Chinese population.
The present research was to assess the relationship between ABCB1 (G2677T/A, C3435T) polymorphisms and lipid homeostasis, as well as risk of liver injury induced by atorvastatin in inpatients from China. The lipids levels (TC, HDL, TG) as well as metabolic enzyme of hepar (ALT, AST, ALP, GGT) in plasma for 162 patients were measured at baseline and after approximately six months of atorvastatin treatment. Polymorphisms of the ABCB1 gene were determined using the Snapshot technique. The associations between genetic polymorphisms and lipids levels, as well as hepar indexes were evaluated at the end of medical treatment. Based on one-way ANOVA analysis, patients with the 2677GG or 3435TT genotypes showed a remarkable decrease percentage when the level of TC was above 4.00 mmol·L-1, separately (P<0.05). There was a significant decrease percentage in the frequency of patients with 2677GG genotype (LDL-C>2.00 mmol·L-1) (P<0.05). The level of ALT in patients with the 2677 GG or 3435CC genotypes displayed a significantly increase percentage, respectively (P<0.05). The ABCB1 G-C haplotype carriers were associated with an increased risk of AILI. The results provide evidence for clinically individualised utilisation of atorvastatin for lipid homeostasis as well as risk of induced liver injury in Chinese population.